



# Leading The Way in Phytocannabinoid Derived Medicines

AGM Presentation

4 November 2020

# Disclaimer

This presentation has been prepared by MGC Pharmaceuticals Ltd (the Company). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

## Forward-looking statements

This presentation may contain certain “forward-looking statements” which may not have been based solely on historical facts, but rather may be based on the Company’s current expectations about future events and results. Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have reasonable basis. However, forward-looking statements:

- a. are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant technical, business, economic, competitive, political and social uncertainties and contingencies;
- b. involve known and unknown risks and uncertainties that could cause actual events or results to differ materially from estimated or anticipated events or results reflected in such forward-looking statements. Such risks include, without limitation, resource risk, metals price volatility, currency fluctuations, increased production costs and variances in ore grade or recovery rates from those assumed in mining plans, as well as political and operational risks in the countries and states in which the Company operates or supplies or sells product to, and governmental regulation and judicial outcomes; and
- c. may include, among other things, statements regarding estimates and assumptions in respect of prices, costs, results and capital expenditure, and are or may be based on assumptions and estimates related to future technical, economic, market, political, social and other conditions.

The words “believe”, “expect”, “anticipate”, “indicate”, “contemplate”, “target”, “plan”, “intends”, “continue”, “budget”, “estimate”, “may”, “will”, “schedule” and similar expressions identify forward-looking statements.

All forward-looking statements contained in this presentation are qualified by the foregoing cautionary statements. Recipients are cautioned that forward-looking statements are not guarantees of future performance and accordingly recipients are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

The Company disclaims any intent or obligation to publicly update any forward-looking statements, whether as a result of new information, future events or results or otherwise.

# Company Highlights

MGC Pharma is a European based, vertically integrated bio-pharma company supplying EU-GMP Phytocannabinoid derived products to patients, with increasing product sales in Australia, NZ, UK, Ireland and Brazil through special access schemes, and new key markets opening in EU and Israel



EU-GMP certified manufacturing facility in Europe, manufacturing phytocannabinoid derived medicines – 3 year GMP license granted



Two Investigational Medicinal Products (IMP's) targeting medical conditions: Refractory epilepsy and dementia & Alzheimer's disease



Additional targeted products in development pipeline with wide IP developments and new Phytotherapeutics line




Rapid growing patient base – delivering affordable cannabinoid medicines to patients. Record weekly sales in September and October 2020



Global distribution via extensive network of commercial partners



Highly qualified management team, supported by leading clinical advisory experts



# Company Strategy

Development and commercialisation of Phytocannabinoid derived products through a vertically integrated, core IP value chain delivering a “Nature to Medicine” business strategy with global distribution capability in place.



## Genetics

High THC >35% strains  
High CBD >20% Strains



## Extraction & Isolation into API

Super Critical (Co<sup>2</sup>)  
Alcohol Extraction



## Clinical Trials

Europe (EMA)  
Australia (TGA)



## Product Development

Europe  
Australia



## Distribution


UK, EU, Australia, NZ  
LATAM, MENA



# Company Mission

*“To Build an Innovative, Vertically Integrated bio-pharma company providing Standardised, Affordable Phytocannabinoid Derived Medicines of the Highest Regulatory Compliance for Targeted global markets and patients”*

## MGC Pharma Total Accumulated Unit Sales – Targeting 5,000 units per month by CYH1 2021



# Distribution and Patient Access



# EU-GMP Manufacturing Facility



Slovenian EU-GMP certified facility has the capacity to manufacture up to 12,000 prescription products per month – 3 year GMP license granted



Based on 5,000 units per month, the Company would be at operating cashflow breakeven, excluding Research costs.\*




Malta facility renovation works commenced with first phase complete, work commenced to extend the facility for ArtemiC™ manufacturing

\* At 5,000 units on a 70% CannEpi® and 30% CogniCann® sales ratio at current market pricing, as previously announced, for both products, the Company expects to start generating positive operating cashflows which will be used to fund R&D and development costs associated with the Company's clinical trials

# Key Global Distribution Partners

Extensive network in place providing access to hospitals, pharmacies and research institutions around the world – Lenis is the Company's wholesaler/exporter to all distributors globally and is also a direct distributor to key European markets



# Key Distribution Partners and Patient Access



Supply and distribution agreement with ONIX in Brazil, with minimum order volumes over a minimum seven-year term



Binding term sheet with K.S. KIM International (subsidiary of SK-Pharma Group) for the sales and distribution of ArtemiC™ in Israel, Russia, CIS countries and the Balkan region



Mexacare provides the sales, marketing and logistics for diagnostic devices and complementary medical products to pharmacies, labs, hospitals and doctors in Germany, Austria and Switzerland



Lyphe are providing the Company direct access to LYPHE's established distribution channels in the UK. Lyphe has extensive networks and has developed a patient-access and distribution ecosystem which positions it as the leader in the UK's rapidly expanding medicinal cannabis market



Distribution Agreement with Anden Bio Naturals S.A. for the exclusive distribution and commercialisation of MGC products in Peru and Bolivia for a five year period



MGC Products are being access through Early Patient Access Schemes in Brazil, UK, Australia and NZ



Strategic Alliance with Australia's leading epilepsy association, Epilepsy Action Australia

A close-up photograph of a female scientist with brown hair, wearing safety glasses and blue nitrile gloves. She is focused on looking through the eyepiece of a white and black compound microscope. Her left hand is positioned near the stage of the microscope. The background is a soft, out-of-focus light blue.

# Product Research & Development



# Clinical R&D – Key Products Trials

3 research areas based on medical experience and large data collections. MGC Pharma has commenced the following clinical trials for three of its products CannEpil®, CogniCann® and ArtemiC™

## Research Areas

## Key Products

### Neurology

- Epilepsy
- Dementia
- Cerebral Palsy

### CannEpil®

Phase IIb Clinical Trial at Schindler Hospital in Israel on the safety and efficacy of CannEpil® as an add on treatment in children and adolescents with refractory epilepsy

### CogniCann®

Phase II Clinical Trial with the University of Notre Dame in Perth, WA to evaluate the potential behavioural benefits CogniCann® may have on patients with dementia and Alzheimer's disease

### Oncology

- Cachexia
- Pain
- Cancer treatment

### Autoimmune

- Anti-Inflammatory
- Anti-Bacterial

### ArtemiC™

Phase II Clinical Trail with Nazareth Hospital EMMS and Hillel Yaffe Hospital in Israel, ArtemiC™ is designed to target viral infections with inflammatory complications, and is currently the safety and efficacy is being evaluated on novel coronavirus 2019 (SARS-CoV-2) infected patients



# ArtemiC™ – COVID-19 Human Patient Phase II Clinical Trial

**ArtemiC™** is a natural water-soluble food supplement containing four natural based ingredients consisting of Artemisinin, Curcumin, Boswellia serrata, and Vitamin C



Powered by:



- Over the years clinical research conducted on these ingredients has consistently demonstrated that they possess immunomodulatory, anti-inflammatory, antioxidant, anti-cancer, antibiotic, and even some anti-viral activity
- **ArtemiC™ uses the MyCell Enhanced™** delivery system technology, a patented platform to deliver natural ingredients more effectively in higher concentrations to the cells, improving bioavailability of natural ingredients
- One avenue to counteract the damage caused by the pandemic is to identify and treat core factors driving the malignant form of COVID-19. These include a prominent disturbance of immunological function ultimately provoking what is known as a “Cytokine Storm” that results in a severe acute respiratory syndrome (SARS) with lethal potential, and severe disruption of additional physiological systems potentially leading to a state of shock and death
- A Phase II human clinical trial testing **ArtemiC™** for treatment of COVID-19 is now completed with results being independently analysed and statistically validated, expected to be published late November/early December 2020.

# R&D – Pre-clinical

Developing medicines that leverage its proprietary medical cannabis formula through clinical trials in Israel, Europe and Australia. Enable future medical product sales across the EU, Australia and other geographies, following the legal and regulatory approvals

## Neurological

**CepaCann** Oral Spray to treat Cerebral Palsy

Preclinical in process

## Oncological & Cancer Side Effects

**Tetrinol** Treatment of Anorexia Cachexia in Cancer Patients

Preclinical in process

**MXOT01GB01** Treatment of Glioblastoma (NIB Slovenia)

Preclinical in process

**MXOT02ME01** Treatment of Melanoma Cancer (RMIT/CannaHub, Aus)

Preclinical in process

**MXOT03PC01** Treatment of Prostate Cancer (RMIT/CannaHub, Aus)

Preclinical in process

## Autoimmune Disease – Inflammatory

**InCann** BiActive Capsule to treat Chron's and IBS (RMIT/CannaHub, Aus)

Preclinical in process

**TopiCann** Topical treatment of Eczema and inflamed skin (Slovenia, EU)

Study Results: 70% Reduction in 4 weeks



# Clinical Advisory Team

Leading experts in the medical cannabis space with unparalleled expertise



**Dr. Jonathan Grunfeld**  
Chief Medical Officer

Certified in Israel, with clinical experience at the MD Anderson Cancer Center, Dr. Grunfeld has spent the last twenty years focusing on Neuro-Oncology, with a focus since 2010 on Cannabis as a treatment for oncological palliative care. Involved in the licensing of care including direct clinical monitoring of circa 5,000 medical cannabis patients in Israel, giving him a unique insight into questions of dosing, patient groups and developing treatment methodology.



**Professor Emeritus Uri Kramer**  
Head of Neurology Product Development

Prof Kramer has a busy paediatric epilepsy clinic with many patients being treated with cannabis. Prof Kramer has run full scale epilepsy trials with cannabis and brings a wealth of experience in various fields (Paediatric Neurology & Child Development). Additionally, Prof Kramer is a former president of the Israeli League Against Epilepsy.



**Professor David Neubauer**

As Head of Department of Child, Adolescent and Developmental Neurology at University Children's Hospital, Ljubljana, Prof Neubauer is widely published and respected, and has dealt with children and adolescents in Neurological contexts for more than thirty years.



**Dr. Nadya Lisovoder**  
Head of Clinical Research (CRO) and Regulatory

15 years of domestic and international experience in academic and clinical studies in the pharmaceutical, diagnostic and medical devices industry. Dr. Lisovoder is a clinical and regulatory expert and has been a clinical adviser to public biotech companies as well as incubator companies, including development of FDA approved products. She has managed clinical trials and has been leading for the Israeli government project of biomedical research in seven hospitals in northern Israel in cooperation with universities, international Pharma companies, global CROs and biotech companies.



# Products



# Phytomedicines – Investigational Products



The Phytomedicines are Plant based products proceeding through clinical trials to obtain marketing authorization, which will allow doctors around the world to prescribe a product with accurate claim to treat symptoms



These investigational products allow MGC Pharma to provide a Rx and OTC medicines at an affordable price point, in comparison to the alternative treatments for untreated conditions



These products are the outcome of years of experience and development of our medical team



CannEpil® designed as a treatment for refractory epilepsy  
CogniCann® designed to improve dementia and Alzheimer's disease patients quality of life



Clinical trials and educational symposiums along side training and patient support platform increasing the access of medicines to the market



# Phytotherapeutics – Mercury Pharma



Line of EU-GMP certified phytotherapeutic products currently available for prescription by medical professionals under special access schemes



The Mercury Pharma brand of products are non-IMP, providing medical professionals a range of products to prescribe as they see best suited for their patient



This line allows MGC to provide a range of products at a more affordable price point, while maintaining the high-quality EU-GMP certification expected from our patients



The brand, 100% owned by MGC Pharma, includes a suite of products created from the same pipeline used for MGC Pharma IMP products



The product line ranges from pure, whole plant CBD extract, through to a high-THC formulation



It also allows MGC Pharma to grow our patient base, provide white label services, and thus increase our revenues, while maintaining focus on continuing development of our IMPs



# Investment Proposition

Fully Integrated Model: Research → Product Development → Commercialise

## Built on Decades of Experience



Technical team of globally recognised scientists and doctors

## Focussed Operations



Core divisions:

- Research and Development
- Manufacturing and Distribution

## Strategically Located



Operational bases close to key markets supported by corporate headquarters

## Robust Product Offering



Portfolio of established and upcoming products targeting key markets

## International Reach



Strong network of research and commercial partners globally

## Strong Market Outlook



Global phytocannabinoid market gaining traction



# mgc pharma



<https://mgcpharma.com.au/>



@mgcpharmaceuticals



@MGC\_Pharma



MGC Pharmaceuticals Ltd

**PR/IR - Media and Capital Partners**

PR – Melissa Hamilton +61 417 750 274  
[melissa.hamilton@mcpartners.com.au](mailto:melissa.hamilton@mcpartners.com.au)

IR – Rod Hinchcliffe +61 412 277 377  
[rod.hinchcliffe@mcpartners.com.au](mailto:rod.hinchcliffe@mcpartners.com.au)